Advertisements



Divi"s stock: Pricing pressure for drug makers can lead to more outsourcing

Analysts at Motilal Oswal Securities expect Divi's earnings before interest, tax, depreciation and amortisation (Ebitda) margin to improve by 400 basis points to 36 per cent.....»»

Category: topSource: business-standardApr 16th, 2018

Alexion"s (ALXN) Soliris Drives Growth Amid Pricing Pressure

Alexion (ALXN) drives growth on consistent demand for lead drug, Soliris. The label expansion of the drug should further propel sales and combat pricing pressu.....»»

Category: worldSource: nytDec 27th, 2018

Why PhaseBio"s stock price more than doubled today

Phase Bio's stock price was up more than double in premarket trading Monday morning after the Malvern biopharmaceutical company published positive early-stage study results from one of its lead new drug candidate over the weekend The company's stock.....»»

Category: topSource: bizjournalsMar 18th, 2019

Solid Biosciences stock falls 73% after preliminary Phase 1/2 trial shows efficacy issues with drug

Shares of Solid Biosciences fell 73% in premarket trade Tuesday after the company said preliminary findings from a Phase 1/2 clinical trial of lead candidate SGT-001 found that patien.....»»

Category: topSource: marketwatchFeb 7th, 2019

Brainstorm Health: Amarin Stock, Drug Pricing Bill, Gaming Disorder Debate

Brainstorm Health Daily: January 10, 2019 Good afternoon, readers. Shares of Ireland-based biopharma Amarin Corporation spiked more than 20% in Thursday trading--a jump that adds to the “fish oil pill” co.....»»

Category: europeSource: fortuneJan 10th, 2019

Trump says drug makers "not living up" to commitments on pricing

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJan 5th, 2019

Pfizer Stock Withstood a Health Care Sector Stumble to Be a 2018 Winner

Drug makers fared worse than most at the end of the year, but Pfizer landed near the top of our rankings......»»

Category: topSource: barronsJan 1st, 2019

Portola stock shoots higher after FDA approval

Portola Pharmaceuticals Inc. shares jumped Monday after the company announced that the Food and Drug Administration had given an approval that should lead to the launch of its Andexxa drug. Portola's stock was .....»»

Category: topSource: marketwatchDec 31st, 2018

Cyclical Pressure, Pricing Weakness To Set Back Hertz, Morgan Stanley Says

If things go right for Hertz Global Holdings Inc (NYSE: HTZ), bulls could celebrate a $34 valuation. If things go wrong, bears are looking at a $2 stock, according to one analyst team. Latest Ratings for HT.....»»

Category: blogSource: benzingaDec 20th, 2018

Congress to Drug Makers: Why Stock Buybacks Over Lowered Drug Prices?

House Democrats say big pharmaceutical companies channeled tax savings to repurchasing shares instead of making some medicines more affordable......»»

Category: smallbizSource: wsjDec 7th, 2018

Asia Markets: China, Hong Kong lead Asian markets lower with financials under pressure

Declines deepened in Asian stock markets as the day progressed Friday......»»

Category: topSource: marketwatchNov 9th, 2018

Pfizer revenue worse than expected as generic competition weighs

Pfizer Inc on Tuesday reported worse-than-expected third quarter revenue and lowered the top end of its full-year sales forecast as generic competition and drug pricing pressure in the United States hurt its older drugs business......»»

Category: topSource: reutersOct 30th, 2018

Mylan stock drops 3% after wipeout of a second quarter

Chief Executive Heather Bresch, who became the poster child for pharmaceutical villainy over EpiPen price hikes in 2016, also critiqued the U.S. drug pricing system......»»

Category: topSource: moneycentralAug 8th, 2018

Mylan stock drops 3% after wipeout of a second quarter

Chief Executive Heather Bresch, who became the poster child for pharmaceutical villainy over EpiPen price hikes in 2016, also critiqued the U.S. drug pricing system......»»

Category: topSource: marketwatchAug 8th, 2018

AbbVie"s Stock Hit By Citron Tweet

In a speech on Wednesday, U.S. Food and Drug Administration commissioner Scott Gottlieb ripped drug makers for blocking competitors from bringing potentially cheaper biosimilar drugs to the market. read more.....»»

Category: blogSource: benzingaJul 19th, 2018

Altria: New Products and Improved Structure Could Lead to a Successful Turnaround

The outlook for Altria may be significantly more positive than the stock market is pricing inRelated Stocks: MO,.....»»

Category: blogSource: gurufocusJun 25th, 2018

FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

InvestorPlace - Stock Market News, Stock Advice & Trading T.....»»

Category: topSource: investorplaceMay 19th, 2018

Infinera stock falls after company warns of pricing pressure, but analysts maintain bullish stances

Shares of Infinera Corp. are down 8.2% in premarket trading Thursday after the optical transmission equipment maker reported better-than-expected quarterly results but spoke of pricing pressure fr.....»»

Category: topSource: marketwatchMay 10th, 2018

Generic drug makers under pressure following Aceto, Novartis news

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 19th, 2018

Bausch Health"s stock shoots up after NDA for psoriasis treatment gets FDA OK

Shares of Bausch Health Companies Inc. shot up 3.6% in afternoon trade Thursday, after the company said its new drug a.....»»

Category: topSource: marketwatch11 hr. 7 min. ago

Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?

With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its opera.....»»

Category: worldSource: nyt12 hr. 6 min. ago